Seoul Pharma Co. Ltd (018680) — Cash Flow-to-Debt Ratio
Seoul Pharma Co. Ltd (018680) has a Cash Flow-to-Debt Ratio of -0.08x as of September 2025, meaning its operating cash flow of ₩-2.66 Billion could theoretically repay 0% of its total liabilities (₩32.70 Billion) in one year. See 018680 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seoul Pharma Co. Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Seoul Pharma Co. Ltd across 13 annual periods. For the full cash flow conversion analysis, see Seoul Pharma Co. Ltd (018680) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Seoul Pharma Co. Ltd (2012–2024)
Year-by-year debt coverage analysis for Seoul Pharma Co. Ltd. Check cash flow quality index of Seoul Pharma Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | ₩-3.01 Billion | ₩31.45 Billion | ▼ -145.0% |
| 2023 | 0.21x | ₩5.26 Billion | ₩24.74 Billion | ▲ +7447.2% |
| 2022 | 0.00x | ₩-78.21 Million | ₩27.01 Billion | ▲ +92.5% |
| 2021 | -0.04x | ₩-1.67 Billion | ₩43.29 Billion | ▼ -124.4% |
| 2020 | 0.16x | ₩5.74 Billion | ₩36.23 Billion | ▲ +129.4% |
| 2019 | 0.07x | ₩2.93 Billion | ₩42.44 Billion | ▲ +326.3% |
| 2018 | -0.03x | ₩-1.23 Billion | ₩40.25 Billion | ▲ +11.3% |
| 2017 | -0.03x | ₩-1.14 Billion | ₩33.08 Billion | ▲ +8.2% |
| 2016 | -0.04x | ₩-1.89 Billion | ₩50.47 Billion | ▼ -229.5% |
| 2015 | 0.03x | ₩1.42 Billion | ₩49.15 Billion | ▼ -6.3% |
| 2014 | 0.03x | ₩1.48 Billion | ₩47.88 Billion | ▲ +384.6% |
| 2013 | -0.01x | ₩-425.00 Million | ₩39.17 Billion | ▼ -104.2% |
| 2012 | 0.26x | ₩9.22 Billion | ₩35.29 Billion | — |